ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Successful salvage of a severe COVID-19 patient previously with lung cancer and radiation pneumonitis by mesenchymal stem cells: a case report and literature review

Huang, Xiaohua; Tan, Xin; Xie, Xiuwen; Jiang, Tingshu; Xiao, Yang; Liu, Zenghui*广州中医药大学; 1
Frontiers in Immunology2024-2-6DOI: 10.3389/fimmu.2024.1321236
8阅读
引用收藏
分享

摘要

During the COVID-19 pandemic, elderly patients with underlying condition, such as tumors, had poor prognoses after progressing to severe pneumonia and often had poor response to standard treatment. Mesenchymal stem cells (MSCs) may be a promising treatment for patients with severe pneumonia, but MSCs are rarely used for patients with carcinoma. Here, we reported a 67-year-old female patient with lung adenocarcinoma who underwent osimertinib and radiotherapy and suffered from radiation pneumonitis. Unfortunately, she contracted COVID-19 and that rapidly progressed to severe pneumonia. She responded poorly to frontline treatment and was in danger. Subsequently, she received a salvage treatment with four doses of MSCs, and her symptoms surprisingly improved quickly. After a lung CT scan that presented with a significantly improved infection, she was discharged eventually. Her primary disease was stable after 6 months of follow-up, and no tumor recurrence or progression was observed. MSCs may be an effective treatment for hyperactive inflammation due to their ability related to immunomodulation and tissue repair. Our case suggests a potential value of MSCs for severe pneumonia that is unresponsive to conventional therapy after a COVID-19 infection. However, unless the situation is urgent, it needs to be considered with caution for patients with tumors. The safety in tumor patients still needs to be observed.

学科与关键词

关键词
severe pneumoniaCOVID-19mesenchymal stem cellslung cancerimmune modulationtissue repairment
相关
加载中…
  • Mesenchymal stem cell treatment for COVID-19
    Xu, Ruonan*; Feng, Zhiqian; Wang, Fu-Sheng*EBioMedicine, 2022, 77: 103920.被引 32
  • Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS
    Xu, Zhiheng; Huang, Yongbo; Zhou, Jianmeng; Deng, Xiumei; He, Weiqun; Liu, Xiaoqing; Li, Yimin; Zhong, Nanshan*; Sang, Ling*Frontiers in Immunology, 2021, 12: 738697.被引 13
  • Stem cell-based therapy for COVID-19
    Chen, Xiaomei; Liu, Bowen; Li, Chao; Wang, Yulian; Geng, Suxia; Du, Xin; Weng, Jianyu; Lai, Peilong*International Immunopharmacology, 2023, 124: 110890.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Immunology
发表日期
2024-02-06
卷期
第 15 卷
页码
1321236
DOI
10.3389/fimmu.2024.1321236
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81903973, 81873426]; Shenzhen Science and Technology Plan Project [JCYJ20220530151613030]; Shenzhen Nanshan District Technology R&D and Creative Design Project Sub-funded Health Science and Technology Project [NS2022004]

作者

  • H

    Huang, Xiaohua (第一作者)

    beijing univ chinese med · 1 · guangzhou univ chinese med

  • T

    Tan, Xin

查看全部 6 位作者收起作者
  • X

    Xie, Xiuwen

    1 · guangzhou univ chinese med

  • J

    Jiang, Tingshu

    yantai yuhuangding hosp

  • X

    Xiao, Yang

  • L

    Liu, Zenghui (通讯)

    1 · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417